Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Ollier disease

Written2008-07Twinkal C Pansuriya, Judith VMG Bovée
Dept of Pathology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

(Note : for Links provided by Atlas : click)
 

Identity

Other namesMultiple enchondromatosis
Dyschondroplasia
Multiple cartilaginous enchondroses
Atlas_Id 10152
Note Ollier disease is a rare skeletal disorder which is characterized by the occurrence of multiple cartilaginous tumours particularly in the medulla of the metaphyses and diaphyses of the short and long tubular bones of the limbs, especially the hands and feet, often with a unilateral predominance.
Inheritance Non-hereditary.

Clinics

Note Ollier disease was first described by Louis Ollier, a French surgeon in early 1800s. The disorder is characterized by the presence of at least three enchondromas. Ollier disease manifests early in childhood and affects both sexes equally. Lesions are distributed unilaterally. In Ollier disease, enchondromas form in the medulla of mainly long bones and it is now clear that Ollier disease is a neoplastic disorder since genetic abnormalities were found in the enchondromas. As a result of the enchondromas the outer cortical layer of the bone becomes thin and more fragile. The disease has a unilateral predominance and may result in limb length discrepancy. The estimated prevalence of Ollier disease is 1/100,000.
Phenotype and clinics Solitary enchondroma is far more common than the occurrence within Ollier disease and is often an incidental finding. Enchondromas can occur anywhere in the skeleton, with a predilection for the hands and feet as well as long bones of upper and lower extremities. The diagnosis is based on roentgenographic appearance as well as clinical features. Lesions affecting the proximal bones are more severe and the region of the knee joint and the lower end of the radius and ulna are particularly common sites and are more prone to pathological fractures. Development of palpable bony masses may cause angular deformity and asymmetric growth. Surgery could be required in case of limb length inequality. The only clinical sign of the disease is severe deformities and bone shortening which may lead to limitations in joint motility. Radiographically, cortical destruction and soft tissue extension are suspicious for malignant transformation of enchondroma. Histologically, enchondromas from Ollier disease patients show more worrisome features such as higher cellularity, pleomorphism and binucleated cells as compared to solitary enchondromas.
 
Neoplastic risk Patients with solitary enchondromas have very low chance (<1%) to develop secondary central chondrosarcoma whereas Ollier patients have an increased life time risk of 15% to 30%. Some patients may develop multiple synchronous or metachronous chondrosarcomas. Pathological fractures can occur at the site of an enchondroma but does not always indicate malignant transformation. In case of benign tumors, the principle symptom is swelling while pain is uncommon and if present, it is usually due to pathological fracture or can be the first sign of malignancy. Increase in tumor size, cortical erosion, extension of the tumor into soft tissues and pain are the signs for malignant transformation. Chondrosarcoma associated with Ollier disease seems to occur more frequently in female as compared to male patients.
Treatment For enchondromas a wait- and -see policy is justified, since these are benign lesions. They can be operated in case of complaints or cosmetic deformity. Enchondromas in phalanges and metacarpals can be curetted and the cavities can be filled with stored cancellous bone or cortical bone graft. In Ollier disease, patients have multiple lesions affecting different regions in the body. Therefore, selection is required for the operative treatment. Surgery can be done in case of complications such as growth defect, pathological fracture and malignant transformation. Lifelong monitoring is required in Ollier patients given the risk of malignant transformation. Leg-length discrepancy in Ollier disease can be corrected using fully implantable lengthening nail. Amputation can be required in case of severe limb shortening and osteotomy can be done to correct deformity and to unite the fragments readily. Ilizarov technique can be used also.
Prognosis The risk of malignant transformation is considerable (up to 35%) which can be life threatening. Most frequently, malignant transformation occurs in long bones and flat bones while this is less common in the hands and feet. Patients with malignant transformation from enchondroma towards grade I, II, III chondrosarcoma have a 5 years survival rate of 90%, 81% and 43% respectively and 10 years survival rate of 83%, 64% and 29% respectively.

Cytogenetics

Cytogenetics of cancer The exact cause of Ollier disease is not known yet but is believed to be a random spontaneous mutation. Previously, a mutation (p.R150C) in PTHR1 (3p22-p21.1) was reported in two out of six patients but an elaborative study on 31 patients failed to detect any mutations in PTHR1. Previously, it has been shown that IHH signalling is very low while PTHLH signaling was active in Ollier disease. Recently, in 3 out of 14 Ollier patients three additional heterozygous missense mutations (p.G121E; p.A122T and p.R255H) were identified in PTHR1. Two mutations, p.G121E and p.A122T were heterozygously present only in enchondroma from the Ollier patient while p. R255H was present in tumor as well as in leukocyte DNA. These mutations were shown to decrease the function of the PTHR1 receptor. Thus, heterozygous PTHR1 mutations may contribute to Ollier disease in a small subset of patients. PTHR1 is a receptor for parathyroid hormone and for parathyroid hormone-related peptide whose activity is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.
Genetic studies on high grade chondrosarcoma of the tibia from a patient with Ollier disease revealed LOH (loss of heterozygosity) for chromosomal bands harbouring the RB1 (13q14) and CDKN2A (9p21) tumor suppressor genes and there was overexpression of the TP53 protein. However, these changes were absent in femoral enchondroma of the same patient.
A del(1)(p11q31.2) has been described in a low grade chondrosarcoma of the scapula in an Ollier patient. Results of cDNA microarray showed similar expression profiling of Ollier disease related tumors as compared to solitary tumors. Array CGH data of four Ollier samples (2 phalangeal enchondromas and 2 grade II chondrosarcomas) showed highly variable genetic abnormalities. One phalangeal enchondroma revealed no alteration while another sample showed complete loss of chromosome 6. The two grade II chondrosarcoma showed gains and losses of several chromosomes. One of the grade II chondrosarcomas showed gain of almost the entire chromosomes 2,5,8,15,19,20,21 and 22 and gain of parts of chromosomes 1,5,7,9,16,17 and 18. The other Ollier disease related chondrosarcoma grade II revealed losses on chromosomes 1,3,4,6,9,10,13,15,16,22 as well as amplifications on chromosomes 6,7,12,14,15,16,17,18,19.

Bibliography

The management of leg-length discrepancy in Ollier's disease with a fully implantable lengthening nail.
Baumgart R, Burklein D, Hinterwimmer S, Thaller P, Mutschler W.
J Bone Joint Surg Br. 2005 Jul;87(7):1000-4.
PMID 15972921
 
Multiple enchondromatosis: a case report.
Benbouazza K, El Hassani S, Hassikou H, Guedira N, Hajjaj-Hassouni N.
Joint Bone Spine. 2002 Mar;69(2):236-9.
PMID 12027322
 
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment.
Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC.
Lancet Oncol. 2005 Aug;6(8):599-607.
PMID 16054571
 
Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes.
Bovee JV, Sciot R, Cin PD, Debiec-Rychter M, van Zelderen-Bhola SL, Cornelisse CJ, Hogendoorn PC.
Diagn Mol Pathol. 2001 Dec;10(4):228-35.
PMID 11763313
 
Malignant progression in multiple enchondromatosis (Ollier's disease): an autopsy-based molecular genetic study.
Bovee JV, van Roggen JF, Cleton-Jansen AM, Taminiau AH, van der Woude HJ, Hogendoorn PC.
Hum Pathol. 2000 Oct;31(10):1299-303.
PMID 11070122
 
A case of multiple chondrosarcomas secondary to severe multiple symmetrical enchondromatosis (Ollier's disease) at an early age.
Bukte Y, Necmioglu S, Nazaroglu H, Kilinc N, Yilmaz F.
Clin Radiol. 2005 Dec;60(12):1306-10.
PMID 16291313
 
Chondrodysplasia (Ollier's disease). Report of a case with a thirty-eight year follow-up.
Cleveland M, Fielding W.
J Bone Joint Surg Am. 1959 Oct;41-A:1341-4.
PMID 13849409
 
PTHR1 mutations associated with Ollier disease result in receptor loss of function.
Couvineau A, Wouters V, Bertrand G, Rouyer C, Gerard B, Boon LM, Grandchamp B, Vikkula M, Silve C.
Hum Mol Genet. 2008 Jun 17. [Epub ahead of print]
PMID 18559376
 
World Health Organization Classification of Tumors. Pathology and genetics. Tumors of Soft Tissue and Bone.
Fletcher CDM, Unni K, Mertens F, (Ed).
Lyon: IARC Press; 2002: 427.
 
Epiphyseal-metaphyseal enchondromatosis. A new clinical entity.
Gabos PG, Bowen JR.
J Bone Joint Surg Am. 1998 Jun;80(6):782-92.
PMID 9655096
 
A mutant PTH/PTHrP type I receptor in enchondromatosis.
Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Juppner H, Andrulis IL, Wunder JS, Alman BA.
Nat Genet. 2002 Mar;30(3):306-10. Epub 2002 Feb 19.
PMID 11850620
 
Bone sarcomas associated with Ollier's disease.
Liu J, Hudkins PG, Swee RG, Unni KK.
Cancer. 1987 Apr 1;59(7):1376-85.
PMID 3815310
 
Radiological Atlas of Bone tumors.
Mulder JD, Schutte HE, Kroon HM, Takonis WK.
1993, Amsterdam: Elsevier.
 
Chondrosarcomas of the base of the skull in Ollier's disease or Maffucci's syndrome--three case reports and review of the literature.
Noel G, Feuvret L, Calugaru V, Hadadi K, Baillet F, Mazeron JJ, Habrand JL.
Acta Oncol. 2004;43(8):705-10.
PMID 15764214
 
Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease.
Ozisik YY, Meloni AM, Spanier SS, Bush CH, Kingsley KL, Sandberg AA.
Cancer Genet Cytogenet. 1998 Sep;105(2):128-33.
PMID 9723029
 
Hereditary multiple exostoses and enchondromatosis.
Pannier S, Legeai-Mallet L.
Best Pract Res Clin Rheumatol. 2008 Mar;22(1):45-54.
PMID 18328980
 
Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations.
Rozeman LB, Szuhai K, Schrage YM, Rosenberg C, Tanke HJ, Taminiau AH, Cleton-Jansen AM, Bovee JV, Hogendoorn PC.
Cancer. 2006 Jul 15;107(2):380-8.
PMID 16779802
 
Chondrodysplasia (Ollier's disease): A Report of a case resembling Osteitis Fibrosa Cystica.
Sanderson GH, Smyth FS.
J Bone Joint Surg Am. 1938; 20:61-67.
 
Ollier's disease treated with grafting using alpha-tricalcium phosphate cement. A case report.
Sasaki D, Hatori M, Abe Y, Kokubun S.
Ups J Med Sci. 2006;111(2):249-56.
PMID 16961181
 
Chondrosarcoma secondary to multiple cartilage diseases. Study of 29 clinical cases and review of the literature.
Schaison F, Anract P, Coste F, De Pinieux G, Forest M, Tomeno B.
Rev Chir Orthop Reparatrice Appar Mot. 1999 Dec;85(8):834-45.
PMID 10637885
 
The malignant potential of enchondromatosis.
Schwartz HS, Zimmerman NB, Simon MA, Wroble RR, Millar EA, Bonfiglio M.
J Bone Joint Surg Am. 1987 Feb;69(2):269-74.
PMID 3805090
 
Two peculiar types of enchondromatosis.
Spranger J, Kemperdieck H, Bakowski H, Opitz JM.
Pediatr Radiol. 1978 Dec 4;7(4):215-9.
PMID 733398
 
Malformation of the humerus in a patient with Ollier disease treated with the Ilizarov technique.
Van Loon P, Lammens J.
J Shoulder Elbow Surg. 2008 Mar-Apr;17(2):e9-11. Epub 2007 Nov 26.
PMID 18036843
 
Treatment of lower limb deformities and limb-length discrepancies with the external fixator in Ollier's disease.
Watanabe K, Tsuchiya H, Sakurakichi K, Yamashiro T, Matsubara H, Tomita K.
J Orthop Sci. 2007 Sep;12(5):471-5. Epub 2007 Sep 28.
PMID 17909933
 

Citation

This paper should be referenced as such :
Pansuriya, TC ; Bovée, JVMG
Ollier disease
Atlas Genet Cytogenet Oncol Haematol. 2009;13(8):608-611.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Tumors/OllierID10152.html


REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:56:21 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.